长期补充海洋ω-3脂肪酸与安慰剂对抑郁或临床相关抑郁症状风险及情绪评分变化的影响:一项随机临床试验
VITAL-DEP是VITAL的辅助研究,纳入18353名美国成人(平均年龄67.5岁,49.2%女性),随机分配至维生素D3 2000 IU/d、海洋ω-3脂肪酸1 g/d鱼油(含465 mg EPA和375 mg DHA)或安慰剂,中位治疗5.3年。ω-3组抑郁或临床相关抑郁症状风险显著高于安慰剂组(651例 vs 583例;13.9 vs 12.3/1000人年;HR 1.13;95%CI 1.01-1.26;P=.03),PHQ-8评分变化均值差0.03分(95%CI -0.01至0.07;P=.19)无显著差异。严重和常见不良事件两组相似。作者结论认为这些发现不支持在成人中使用ω-3补充剂预防抑郁。
要点
- 在≥50岁无临床相关抑郁症状成人中,ω-3组抑郁或临床相关抑郁症状风险显著高于安慰剂组(651例 vs 583例;13.9 vs 12.3/1000人年;HR 1.13;95%CI 1.01-1.26;P=.03)。
- ω-3与安慰剂组PHQ-8情绪评分变化均值差0.03分(95%CI -0.01至0.07;P=.19),无显著差异。
- ω-3与维生素D交互作用检验不显著(P for interaction=.14)。
- 严重和常见不良事件两组相似:主要心血管事件2.7% vs 2.9%,全因死亡3.3% vs 3.1%,自杀0.02% vs 0.01%,消化道出血2.6% vs 2.7%,易瘀伤24.8% vs 25.1%,胃部不适或疼痛35.2% vs 35.1%。
- 作者结论认为这些发现不支持在成人中使用ω-3补充剂预防抑郁。
适用人群与场景
- VITAL-DEP纳入18353名成人,来自VITAL随机试验的25871名美国成人;其中16657名有 incident 抑郁风险(无既往抑郁),1696名有复发抑郁风险(既往抑郁但过去2年无抑郁)。
- 平均年龄67.5岁(SD 7.1),49.2%为女性;基线无临床相关抑郁症状。
诊断标准与关键阈值
- 抑郁或临床相关抑郁症状定义为 incident + recurrent 病例的总和。
- 情绪评分采用8项患者健康问卷(PHQ-8)抑郁量表。
处置流程与药物剂量
- 随机2×2析因分配至维生素D3 2000 IU/d、海洋ω-3脂肪酸1 g/d鱼油(含465 mg二十碳五烯酸和375 mg二十二碳六烯酸)或安慰剂;9171名随机至ω-3,9182名随机至匹配安慰剂。
- 随机化时间为2011年11月至2014年3月;随机治疗于2017年12月31日结束;中位治疗 duration 5.3年。
研究设计与关键结果
- 随机对照试验(VITAL-DEP,VITAL辅助研究),样本量18353,随机化2011年11月至2014年3月,治疗结束2017年12月31日;90.3%完成试验(存活者中93.5%);中位治疗5.3年。
- 主要终点:ω-3组抑郁或临床相关抑郁症状651例(13.9/1000人年)vs 安慰剂组583例(12.3/1000人年);HR 1.13;95%CI 1.01-1.26;P=.03。
- 情绪评分:ω-3 vs 安慰剂PHQ-8评分变化均值差0.03分(95%CI -0.01至0.07;P=.19)。
- 交互作用:ω-3与维生素D交互作用检验不显著(P for interaction=.14)。
- 不良事件(ω-3 vs 安慰剂):主要心血管事件2.7% vs 2.9%,全因死亡3.3% vs 3.1%,自杀0.02% vs 0.01%,消化道出血2.6% vs 2.7%,易瘀伤24.8% vs 25.1%,胃部不适或疼痛35.2% vs 35.1%。
证据类型、等级与局限
- 证据类型:随机对照试验(RCT),VITAL-DEP辅助研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为这些发现不支持在成人中使用ω-3补充剂预防抑郁。
- 在≥50岁无临床相关抑郁症状成人中,ω-3补充剂1 g/d鱼油较安慰剂小幅但显著增加抑郁或临床相关抑郁症状风险(HR 1.13;95%CI 1.01-1.26;P=.03),情绪评分无显著差异(均值差0.03分;95%CI -0.01至0.07;P=.19)。
指南或共识出处
- VITAL-DEP(Vitamin D and Omega-3 Trial-Depression Endpoint Prevention)辅助研究;临床试验注册号NCT01696435和NCT01169259。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Marine omega-3 fatty acid (omega-3) supplements have been used to treat depression but their ability to prevent depression in the general adult population is unknown.
OBJECTIVE: To test effects of omega-3 supplementation on late-life depression risk and mood scores.
DESIGN, SETTING, AND PARTICIPANTS: A total of 18 353 adults participated in the VITAL-DEP (Vitamin D and Omega-3 Trial-Depression Endpoint Prevention) ancillary study to VITAL, a randomized trial of cardiovascular disease and cancer prevention among 25 871 US adults. There were 16 657 at risk of incident depression (no previous depression) and 1696 at risk of recurrent depression (previous depression, but not for the past 2 years). Randomization occurred from November 2011 through March 2014; randomized treatment ended on December 31, 2017.
INTERVENTIONS: Randomized 2 × 2 factorial assignment to vitamin D3 (2000 IU/d), marine omega-3 fatty acids (1 g/d of fish oil, including 465 mg of eicosapentaenoic acid and 375 mg of docosahexaenoic acid) or placebo; 9171 were randomized to omega-3 and 9182 were randomized to matching placebo.
MAIN OUTCOMES AND MEASURES: Prespecified coprimary outcomes were risk of depression or clinically relevant depressive symptoms (total of incident + recurrent cases); mean difference in mood score (8-item Patient Health Questionnaire [PHQ-8] depression scale).
RESULTS: Among 18 353 participants who were randomized (mean age, 67.5 [SD, 7.1] years; 49.2% women), 90.3% completed the trial (93.5% among those alive at the end of the trial); the median treatment duration was 5.3 years. The test for interaction between the omega-3 and the vitamin D agents was not significant (P for interaction = .14). Depression risk was significantly higher comparing omega-3 (651 events, 13.9 per 1000 person-years) with placebo (583 events, 12.3 per 1000 person-years; hazard ratio [HR], 1.13; 95% CI, 1.01-1.26; P = .03). No significant differences were observed comparing omega-3 with placebo groups in longitudinal mood scores: the mean difference in change in PHQ-8 score was 0.03 points (95% CI, -0.01 to 0.07; P = .19). Regarding serious and common adverse events, the respective prevalence values in omega-3 vs placebo groups were major cardiovascular events (2.7% vs 2.9%), all-cause mortality (3.3% vs 3.1%), suicide (0.02% vs 0.01%), gastrointestinal bleeding (2.6% vs 2.7%), easy bruising (24.8% vs 25.1%), and stomach upset or pain (35.2% vs 35.1%).
CONCLUSIONS AND RELEVANCE: Among adults aged 50 years or older without clinically relevant depressive symptoms at baseline, treatment with omega-3 supplements compared with placebo yielded mixed results, with a small but statistically significant increase in risk of depression or clinically relevant depressive symptoms but no difference in mood scores, over a median follow-up of 5.3 years. These findings do not support the use of omega-3 supplements in adults to prevent depression.
TRIAL REGISTRATION: ClinicalTrials.gov Identifiers: NCT01696435 and NCT01169259.
参考来源
- Okereke OI, Vyas CM, Mischoulon D, et al. Effect of Long-term Supplementation With Marine Omega-3 Fatty Acids vs Placebo on Risk of Depression or Clinically Relevant Depressive Symptoms and on Change in Mood Scores: A Randomized Clinical Trial. JAMA. 2021. PMID: 34932079. doi:10.1001/jama.2021.21187
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。